Market Cap 2.56B
Revenue (ttm) 0.00
Net Income (ttm) -422.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,281,100
Avg Vol 1,804,712
Day's Range N/A - N/A
Shares Out 146.66M
Stochastic %K 75%
Beta 1.39
Analysts Strong Sell
Price Target $31.60

Company Profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Synd...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 866 8547
Address:
161 Oyster Point Boulevard, South San Francisco, United States
Drashkawisha
Drashkawisha Nov. 14 at 12:12 PM
$DNLI The Case: A long-term neurodegeneration play based on its "Transport Vehicle" (TV) platform. Fact: The thesis is dependent on the TV platform's ability to successfully cross the blood-brain barrier. Value is supported by major partnerships with Biogen and Sanofi.
0 · Reply
Drashkawisha
Drashkawisha Nov. 13 at 11:43 AM
$DNLI damn….. I’m good
0 · Reply
moneybag888
moneybag888 Nov. 12 at 10:42 PM
0 · Reply
moneybag888
moneybag888 Nov. 12 at 9:33 PM
1 · Reply
SuperGreenToday
SuperGreenToday Nov. 12 at 7:25 PM
$DNLI Share Price: $17.25 Contract Selected: Jun 18, 2026 $20 Calls Buy Zone: $2.08 – $2.57 Target Zone: $3.92 – $4.79 Potential Upside: 78% ROI Time to Expiration: 217 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BobBijawklah
BobBijawklah Nov. 12 at 12:24 AM
$DNLI mod twenties valuation easy . Ceo ryan watts is a genius and a genuine leader who gets the most out his people. There are two other programs that will bring more revenue to the mix. And a huge potential new partnership to carry payloads across brain blood barrier. Pt 26 by pdufa mark and my post
0 · Reply
moneybag888
moneybag888 Nov. 11 at 10:15 PM
$ARGX $DNLI #TimVanthe 🐐
0 · Reply
RunnerSignals
RunnerSignals Nov. 11 at 9:15 PM
Market Warriors Rise Again ️From red to roaring green! ​$VELO.X $IRWD $HROW $DNLI $BFLY morning dips, evening wins
1 · Reply
moneybag888
moneybag888 Nov. 11 at 9:06 PM
$DNLI $ARGX $RIGL 🚀🚀🚀🚀 #BeFirst
0 · Reply
moneybag888
moneybag888 Nov. 11 at 7:24 PM
0 · Reply
Latest News on DNLI
The Best Small-Cap Stocks to Buy Now

Aug 12, 2025, 9:47 AM EDT - 3 months ago

The Best Small-Cap Stocks to Buy Now

KYMR WAY


Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Mar 20, 2025, 2:16 PM EDT - 8 months ago

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead


Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

Jan 15, 2025, 2:26 PM EST - 10 months ago

Why Is Denali Therapeutics Stock Trading Higher On Wednesday?


Denali Therapeutics ALS drug fails in mid-stage trial

Jan 6, 2025, 4:43 PM EST - 11 months ago

Denali Therapeutics ALS drug fails in mid-stage trial


Denali Has A Neurodegenerative Edge Despite Market Skepticism

Nov 16, 2024, 8:56 AM EST - 1 year ago

Denali Has A Neurodegenerative Edge Despite Market Skepticism


Denali's New Summit: Changing Hunter Syndrome Landscape

Oct 2, 2023, 5:26 AM EDT - 2 years ago

Denali's New Summit: Changing Hunter Syndrome Landscape


MPS II And Beyond: Implications Of Denali's Promising Pipeline

Jul 23, 2023, 12:51 AM EDT - 2 years ago

MPS II And Beyond: Implications Of Denali's Promising Pipeline


Drashkawisha
Drashkawisha Nov. 14 at 12:12 PM
$DNLI The Case: A long-term neurodegeneration play based on its "Transport Vehicle" (TV) platform. Fact: The thesis is dependent on the TV platform's ability to successfully cross the blood-brain barrier. Value is supported by major partnerships with Biogen and Sanofi.
0 · Reply
Drashkawisha
Drashkawisha Nov. 13 at 11:43 AM
$DNLI damn….. I’m good
0 · Reply
moneybag888
moneybag888 Nov. 12 at 10:42 PM
0 · Reply
moneybag888
moneybag888 Nov. 12 at 9:33 PM
1 · Reply
SuperGreenToday
SuperGreenToday Nov. 12 at 7:25 PM
$DNLI Share Price: $17.25 Contract Selected: Jun 18, 2026 $20 Calls Buy Zone: $2.08 – $2.57 Target Zone: $3.92 – $4.79 Potential Upside: 78% ROI Time to Expiration: 217 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BobBijawklah
BobBijawklah Nov. 12 at 12:24 AM
$DNLI mod twenties valuation easy . Ceo ryan watts is a genius and a genuine leader who gets the most out his people. There are two other programs that will bring more revenue to the mix. And a huge potential new partnership to carry payloads across brain blood barrier. Pt 26 by pdufa mark and my post
0 · Reply
moneybag888
moneybag888 Nov. 11 at 10:15 PM
$ARGX $DNLI #TimVanthe 🐐
0 · Reply
RunnerSignals
RunnerSignals Nov. 11 at 9:15 PM
Market Warriors Rise Again ️From red to roaring green! ​$VELO.X $IRWD $HROW $DNLI $BFLY morning dips, evening wins
1 · Reply
moneybag888
moneybag888 Nov. 11 at 9:06 PM
$DNLI $ARGX $RIGL 🚀🚀🚀🚀 #BeFirst
0 · Reply
moneybag888
moneybag888 Nov. 11 at 7:24 PM
0 · Reply
Drashkawisha
Drashkawisha Nov. 11 at 2:46 PM
0 · Reply
moneybag888
moneybag888 Nov. 10 at 3:51 PM
0 · Reply
moneybag888
moneybag888 Nov. 10 at 3:48 PM
0 · Reply
Drashkawisha
Drashkawisha Nov. 10 at 2:10 PM
$DNLI The 3-month PDUFA delay to April 5, 2026, is frustrating but fundamental thesis remains unchanged. Crucially, the delay is purely procedural due to a "major amendment" of additional data, NOT due to any safety or efficacy concerns. The science is solid. More time for waiting, but the potential validation for the entire BBB platform is still the main event. Patience is key.
0 · Reply
moneybag888
moneybag888 Nov. 7 at 8:35 PM
$DNLI #BeFirst $ARGX $RIGL
0 · Reply
rootabaga
rootabaga Nov. 7 at 3:09 PM
$DNLI does anyone know details about the reported increased losses they have experienced “amid strategic collaborations “ ?
0 · Reply
Biodro
Biodro Nov. 7 at 1:31 AM
$ARGX $DNLI interesting now they have 2 board members now on Denali’s board…Steve Krognes & Tim 🤔🤔🤔🤔
1 · Reply
Biodro
Biodro Nov. 7 at 1:28 AM
$DNLI interesting now they have 2 $ARGX board members on Denali’s board…Steve Krognes & Tim 🤔🤔🤔🤔
0 · Reply
dgbio
dgbio Nov. 6 at 10:19 PM
$DNLI completed enrollment in the ongoing Phase 1/2 study of DNL126 to support an accelerated approval path in MPS IIIA, also known as Sanfilippo syndrome type A. The data will be presented in a platform presentation at the 2026 WORLDSypmosium in February.
0 · Reply
dgbio
dgbio Nov. 6 at 10:08 PM
$DNLI Two new regulatory applications submitted to initiate clinical studies with DNL628 (OTV:MAPT) for Alzheimer’s disease and DNL952 (ETV:GAA) for Pompe disease
0 · Reply
dgbio
dgbio Nov. 6 at 9:57 PM
$DNLI Carole Ho, long-time CMO, is leaving to head Neuroscience at Lilly. It validates the strength of Denali's programs and gives some ideas about possible interactions with Lilly.
0 · Reply
DoctrBenway
DoctrBenway Nov. 4 at 6:54 PM
$DNLI I’ve got plenty of this, but I would prefer at this loading-zone. Very
0 · Reply